151.90
price up icon2.57%   3.81
after-market Handel nachbörslich: 151.90
loading
Schlusskurs vom Vortag:
$148.09
Offen:
$148.51
24-Stunden-Volumen:
293.14K
Relative Volume:
0.83
Marktkapitalisierung:
$4.39B
Einnahmen:
$290.51M
Nettoeinkommen (Verlust:
$89.16M
KGV:
50.80
EPS:
2.99
Netto-Cashflow:
$119.18M
1W Leistung:
+2.82%
1M Leistung:
+14.68%
6M Leistung:
-1.02%
1J Leistung:
-26.57%
1-Tages-Spanne:
Value
$148.51
$152.80
1-Wochen-Bereich:
Value
$146.35
$153.74
52-Wochen-Spanne:
Value
$122.80
$219.34

Krystal Biotech Inc Stock (KRYS) Company Profile

Name
Firmenname
Krystal Biotech Inc
Name
Telefon
(412) 586-5830
Name
Adresse
2100 WHARTON STREET, PITTSBURGH, PA
Name
Mitarbeiter
275
Name
Twitter
@KrystalBiotech
Name
Nächster Verdiensttermin
2024-11-04
Name
Neueste SEC-Einreichungen
Name
KRYS's Discussions on Twitter

Vergleichen Sie KRYS mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
KRYS
Krystal Biotech Inc
151.90 4.27B 290.51M 89.16M 119.18M 2.99
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.13 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.28 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.59 29.19B 3.81B -644.79M -669.77M -6.24

Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-05 Eingeleitet Jefferies Buy
2024-08-06 Herabstufung Citigroup Buy → Neutral
2023-11-20 Eingeleitet Goldman Buy
2023-10-24 Eingeleitet Cantor Fitzgerald Overweight
2023-10-12 Eingeleitet Citigroup Buy
2023-09-07 Eingeleitet Berenberg Buy
2023-04-18 Eingeleitet Stifel Buy
2023-02-28 Hochstufung Goldman Neutral → Buy
2022-08-25 Herabstufung Goldman Buy → Neutral
2022-01-18 Eingeleitet BofA Securities Buy
2021-07-20 Hochstufung Goldman Neutral → Buy
2020-09-18 Eingeleitet B. Riley FBR Buy
2020-06-04 Eingeleitet Evercore ISI Outperform
2019-09-24 Eingeleitet Goldman Neutral
2019-08-06 Bestätigt H.C. Wainwright Buy
2019-06-24 Bestätigt Chardan Capital Markets Buy
2019-06-24 Bestätigt H.C. Wainwright Buy
2019-05-30 Eingeleitet Guggenheim Buy
2018-09-11 Eingeleitet Cantor Fitzgerald Overweight
Alle ansehen

Krystal Biotech Inc Aktie (KRYS) Neueste Nachrichten

pulisher
Jul 22, 2025

What analysts say about Krystal Biotech Inc. stockFast-track wealth growth - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What drives Krystal Biotech Inc. stock priceRapidly growing investment returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Krystal Biotech Inc. Stock Analysis and ForecastDynamic growth stocks - Autocar Professional

Jul 22, 2025
pulisher
Jul 22, 2025

Is Krystal Biotech Inc. a good long term investmentOutstanding capital returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What makes Krystal Biotech Inc. stock price move sharplyTop Gaining Low Risk Assets - Newser

Jul 22, 2025
pulisher
Jul 18, 2025

Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Sold by Nisa Investment Advisors LLC - Defense World

Jul 18, 2025
pulisher
Jul 17, 2025

$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today - Benzinga

Jul 17, 2025
pulisher
Jul 17, 2025

Hedge Fund and Insider Trading News: Bobby Jain, Bill Ackman, Ken Griffin, Sylebra Capital Management, Millennium Management, Krystal Biotech Inc (KRYS), and More - Insider Monkey

Jul 17, 2025
pulisher
Jul 17, 2025

William Blair Predicts Lower Earnings for Krystal Biotech - Defense World

Jul 17, 2025
pulisher
Jul 16, 2025

Krishnan Krish S, Krystal Biotech CEO, sells $5.39 million in stock - Investing.com Canada

Jul 16, 2025
pulisher
Jul 16, 2025

Krystal biotech (KRYS) director Suma Krishnan sells $5.39m in stock By Investing.com - Investing.com South Africa

Jul 16, 2025
pulisher
Jul 16, 2025

Krystal biotech (KRYS) director Suma Krishnan sells $5.39m in stock - Investing.com Australia

Jul 16, 2025
pulisher
Jul 16, 2025

Citi Maintains Krystal Biotech(KRYS.US) With Hold Rating, Raises Target Price to $176 - 富途牛牛

Jul 16, 2025
pulisher
Jul 16, 2025

Krystal Biotech, Inc. (NASDAQ:KRYS) Position Trimmed by Bank of New York Mellon Corp - Defense World

Jul 16, 2025
pulisher
Jul 16, 2025

why krystal biotech inc. stock attracts strong analyst attentionControlled Risk High Reward Plan - Newser

Jul 16, 2025
pulisher
Jul 16, 2025

M&T Bank Corp Purchases New Shares in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World

Jul 16, 2025
pulisher
Jul 16, 2025

Krystal Biotech FY2025 EPS Estimate Lowered by William Blair - Defense World

Jul 16, 2025
pulisher
Jul 15, 2025

Why Krystal Biotech Inc. stock attracts strong analyst attentionFree Stock Investment Discussion Area - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Krystal Biotech Inc. stock performs during market volatilityPortfolio Boosting Stock Alerts - Newser

Jul 15, 2025
pulisher
Jul 14, 2025

Krystal Biotech doses first patient in EMERALD-1 phase 1/2 trial for neurotrophic keratitis - Ophthalmology Times

Jul 14, 2025
pulisher
Jul 14, 2025

Teacher Retirement System of Texas Has $1.05 Million Stock Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World

Jul 14, 2025
pulisher
Jul 14, 2025

William Blair Forecasts Lower Earnings for Krystal Biotech - Defense World

Jul 14, 2025
pulisher
Jul 12, 2025

William Blair Expects Lower Earnings for Krystal Biotech - Defense World

Jul 12, 2025
pulisher
Jul 10, 2025

KRYS Begins Dosing With Gene Therapy in Rare Eye Disease, Stock Up - Yahoo Finance

Jul 10, 2025
pulisher
Jul 10, 2025

Krystal Biotech begins phase 1/2 trial of eye drop gene therapy for NK By Investing.com - Investing.com South Africa

Jul 10, 2025
pulisher
Jul 09, 2025

Krystal Biotech begins phase 1/2 trial of eye drop gene therapy for NK - Investing.com Nigeria

Jul 09, 2025
pulisher
Jul 09, 2025

Transcript : Krystal Biotech, Inc.Special Call - MarketScreener

Jul 09, 2025
pulisher
Jul 09, 2025

Krystal Biotech Begins Phase 1/2 Trial for KB801 - TipRanks

Jul 09, 2025
pulisher
Jul 09, 2025

Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitis - The Manila Times

Jul 09, 2025
pulisher
Jul 09, 2025

Krystal Biotech Initiates First Patient Dosing in Phase 1/2 EMERALD-1 Trial for KB801 in Neurotrophic Keratitis - Nasdaq

Jul 09, 2025
pulisher
Jul 09, 2025

Revolutionary Eye Drop Gene Therapy: Krystal Biotech Targets 68,000 Patient NK Market in New Trial - Stock Titan

Jul 09, 2025
pulisher
Jul 09, 2025

New York State Teachers Retirement System Grows Position in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World

Jul 09, 2025
pulisher
Jul 09, 2025

Allspring Global Investments Holdings LLC Decreases Stake in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World

Jul 09, 2025

Finanzdaten der Krystal Biotech Inc-Aktie (KRYS)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.80
price up icon 0.51%
$36.10
price up icon 1.26%
$102.92
price up icon 0.14%
$26.54
price up icon 0.76%
$111.44
price up icon 2.32%
biotechnology ONC
$295.59
price up icon 1.25%
Kapitalisierung:     |  Volumen (24h):